Remepy
Sheila Oren, MD MBA is currently the Chief Parkinson's Program at Remepy and the Senior Medical Advisor at SOREN Medical Consulting. With a background in medical strategy, clinical development, and regulatory affairs, Sheila has held various leadership positions in the pharmaceutical industry at companies such as Anabasis LTD, Pharma Two B, Neuroderm, Teva Pharmaceuticals, and Boehringer Ingelheim. Sheila earned their MD from the School of Medicine, Tel Aviv University, Israel, and an MBA from Reichman University. Additionally, Sheila completed an Executive Leadership Program at Harvard Business School.
Remepy
Remepy is Pioneering Hybrid Drugs™. We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™. Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug. The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.